A subcutaneous tunneling device includes a shaft having a bend, a catheter connector extending from a distal end of the shaft distal of the bend, and a sleeve. The catheter connector can include a body having a gripping portion, and a barbed extension distal of the body configured for insertion into a distal opening of a catheter. The sleeve is slidably mounted on the shaft and has a retracted position exposing the catheter connector for coupling the catheter to the catheter connector via the barbed extension, and an extended position covering the catheter connector and a distal end of the catheter.

Dialysis is enhanced by using nanoclay sorbents to better absorb body wastes in a flow-through system. The nanoclay sorbents, using montmorillonite, bentonite, and other clays, absorb significantly more ammonium, phosphate, and creatinine, and the like, than conventional sorbents. The montmorillonite, the bentonite, and the other clays may be used in wearable systems, in which a dialysis fluid is circulated through a filter with the nanoclay sorbents. Waste products are absorbed by the montmorillonite, the bentonite, and the other clays and the dialysis fluid is recycled to a patient's peritoneum. Using an ion-exchange capability of the montmorillonite, the bentonite, and the other clays, waste ions in the dialysis fluid are replaced with desirable ions, such as calcium, magnesium, and bicarbonate. The nanoclay sorbents are also useful for refreshing a dialysis fluid used in hemodialysis and thus reducing a quantity of the dialysis fluid needed for the hemodialysis.

Systems, devices, and methods of the present disclosure assist with management of tubes and hoses during surgical procedures. The systems, devices, and methods provide for the proper opening and closing of tubes to facilitate performance of steps in a surgical procedure. Systems, devices, and methods of the present disclosure control fluid delivery to and from a medical device, including devices for tissue processing and cleaning.

A surgical fluid management system delivers fluid for distending a uterine cavity to allow cutting and extraction of uterine fibroid tissue, polyps and other abnormal uterine tissue. The system comprises a fluid source, fluid deliver lines, one or more pumps, and a filter for re-circulating the distension fluid between the source and the uterine cavity. A controller can monitor fluid retention by the patient.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a multilumen flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

A blood reintroduction system may include a canister configured to collect blood. The system may include an inlet configured to be fluidly connected to a first tubing in fluid communication with an aspiration system configured to apply aspiration to a vasculature of a patient. The system may include a first outlet configured to be fluidly connected to a second tubing in fluid communication with an aspiration pump. The system may include a second outlet configured to interact with a blood reintroduction device, wherein the blood reintroduction device is configured to withdraw the blood collected inside the canister. The system may include a filter positioned inside a flow path leading to the second outlet.

An apparatus for extracorporeal blood treatment comprises a control unit (100) connected to a blood pump (10) configured to deliver a blood flow rate in a blood circuit of the apparatus (1), to a diuretic pump (27) configured to deliver a flow rate (Q.sub.d) of a 5diuretic (e.g. furosemide) and to an osmotic agent pump (30) configured to deliver a flow rate (Q.sub.oa) of an osmotic agent (e.g. albumin) to be infused in the blood circuit or in the vascular system of the patient (P). The control unit (100) is configured for receiving at least one input patient parameter (e.g. blood 10pressure) and/or at least one input apparatus parameter (e.g. access pressure) and, during an extracorporeal blood treatment, to drive the diuretic pump (27) and/or the osmotic agent pump (30) as a function of said at least one input patient parameter and/or as a function of at least one input apparatus parameter, in order to15achieve an improved and better fluid removal from the patient (P).

An apparatus for treating a patient suffering from acquired Transthyretin Amyloidosis includes a blood dialysis circuit with a pump for pumping the patient's blood that has been pretreated with magnetic nanoparticles through the dialysis circuit, and a transthyretin amyloid (TTR) protein separation component downstream of the pump and structured and disposed to separate the TTR proteins from the patient's blood by magnetic attraction as a result of the magnetic nanoparticles infiltrating the TTR proteins prior to circulation through the circuit. The circuit further includes a pressure gauge and a downstream end connection to the patient's venous blood flow for returning the patient's blood to the patient after removal of the TTR proteins.

Multi-lumen catheters with improved tip configurations, including a triple-lumen catheter which may be useful for apheresis. In one variation, the catheter has three lumens with distal openings angularly spaced apart and staggered axially with respect to one another. In another variation, the catheter has two lumens exiting distally and one centrally positioned lumen exiting proximally. A third variation is a catheter with a single distal opening and two proximal openings. The staggered lumen openings along the axial length of the catheter may decrease recirculation while maximizing flow rates.

The invention relates to a blood line (108) comprising an infusion site (145) intended to inject into the line a solution comprising: a first main channel (200) having a first passage section, a second main channel (220) having a second passage section, means for the formation (210) of a turbulence area located downstream from the first main channel, located upstream from the second main channel, these formation means comprising a first fluid passage means (224) defining a reduction (225) in the passage section and whose smallest passage section is smaller than the first passage section and smaller than the second fluid passage section, a secondary channel (230) comprising an inlet (231) for letting in the solution and an outlet (232) in fluid communication with the first main channel or the means for the formation of a turbulence area or the second main channel.